{"id":25745,"date":"2026-06-22T10:13:11","date_gmt":"2026-06-22T10:13:11","guid":{"rendered":"https:\/\/globalnewstoday.uk\/index.php\/2026\/06\/22\/3-of-wall-streets-favorite-stocks-to-consider-right-now-stockstory\/"},"modified":"2026-06-22T10:13:11","modified_gmt":"2026-06-22T10:13:11","slug":"3-of-wall-streets-favorite-stocks-to-consider-right-now-stockstory","status":"publish","type":"post","link":"https:\/\/globalnewstoday.uk\/index.php\/2026\/06\/22\/3-of-wall-streets-favorite-stocks-to-consider-right-now-stockstory\/","title":{"rendered":"3 of Wall Street\u2019s Favorite Stocks to Consider Right Now – StockStory"},"content":{"rendered":"

June 22, 2026
The stocks in this article have caught Wall Street\u2019s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. That said, here are three stocks where Wall Street\u2019s excitement appears well-founded.
Consensus Price Target: $548.69 (21.1% implied return)
Founded in 1989 with a mission to create medicines that treat the underlying causes of disease rather than just symptoms, Vertex Pharmaceuticals (NASDAQ:VRTX) develops and markets transformative medicines for serious diseases, with a focus on cystic fibrosis, sickle cell disease, and pain management.
Why Are We Fans of VRTX?<\/strong>
At $452.99 per share, Vertex Pharmaceuticals trades at 23.1x forward P\/E. Is now the time to initiate a position? Find out in our full research report, it\u2019s free<\/a>.
Consensus Price Target: $387.23 (25.6% implied return)
With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE:SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions.
Why Are We Positive on SYK?<\/strong>
Stryker\u2019s stock price of $308.42 implies a valuation ratio of 19.7x forward P\/E. Is now the right time to buy? See for yourself in our in-depth research report, it\u2019s free<\/a>.
Consensus Price Target: $107.50 (31% implied return)
Formerly known as Meta Financial until its 2022 rebranding, Pathward Financial (NASDAQ:CASH) provides banking-as-a-service solutions and commercial finance products, enabling partners to offer financial services like prepaid cards, payment processing, and lending options.
Why Do We Love CASH?<\/strong>
Pathward Financial is trading at $82.05 per share, or 2x forward P\/B. Is now the time to initiate a position? Find out in our full research report, it\u2019s free<\/a>.
ONE MORE THING: Top 5 Growth Stocks.<\/strong> The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it\u2019s flagging this month \u2014 FREE. Get Our Top 5 Growth Stocks for Free HERE<\/strong><\/a>.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today<\/a>.
\u00a92026 StockStory
Data sources: actuals and consensus estimates from StockStory<\/a>, S&P Global Market Intelligence<\/a>, and Visible Alpha<\/a>. Market data from Massive<\/a>.
Provided for general information purposes only and does not constitute investment advice or a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific individual. Information on our investment framework and performance methodology is available here<\/a>.
Copyright 2026, S&P Global Market Intelligence (and its affiliates as applicable). All rights reserved.<\/a><\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

June 22, 2026The stocks in this article have caught Wall Street\u2019s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory. […]<\/p>\n","protected":false},"author":1,"featured_media":25746,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-25745","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business"],"_links":{"self":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/25745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/comments?post=25745"}],"version-history":[{"count":0,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/25745\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media\/25746"}],"wp:attachment":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media?parent=25745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/categories?post=25745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/tags?post=25745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}